Scientific Publications

Publications that have been authored/co-authored by 'the RNA people':

mRNA mediates passive vaccination against infectious agents, toxins, and tumors
Thran et al., EMBO Molecular Medicine, August 2017. More...

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial
Martin Alberer et al., The Lancet, July 2017. More...

A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects
Annett Ziegler et al., Journal of Immunology, January 2017. More... 

Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response
Edwards DK et al., Journal of Translational Medicine, January 2017. More...

Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy
Hong et al., OncoImmunology, December 2016. More...

Immunological effects of a novel RNA-based adjuvant in liver cancer patients
Circelli et al., Cancer Immunology Immunotherapy, November 2016. More... 

Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity
Kowalczyk A et al., Vaccine, July 2016. More...

An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs
Kramps T et al., PLOS Neglected Tropical Diseases, June 2016. More...

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
Kübler H et al., Journal for Immunotherapy of Cancer, July 2015. More...

A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile
Heidenreich R et al, International Journal of Cancer, July 2015. More...

Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals
Schlake T et al, Molecular Therapy, June 2015. More...

mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer
Rausch S et al, Human Vaccines & Immunotherapeutics, Jan. 2015. More...

mRNA-based vaccines synergize with radiation therapy to eradicate established tumors
Fotin-Mleczek M et al, Radiation Oncology, Aug. 2014. More...

A development, that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs
Kallen K-J et al, Therapeutic Advances in Vaccines, Nov. 2013. More...

The regulatory landscape for actively personalized cancer immunotherapies
Cedrik M Britten et al, Nature Biotechnology, Oct. 2013. More...

A novel, disruptive vaccination technology, Self-adjuvanted RNActive® vaccines
Kallen K-J et al, Human Vaccines & Immunotherapeutics, Oct. 2013. More...

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection
Petsch B et al., Nature Biotechnology, Nov. 2012. More...

Developing mRNA-vaccine technologies
Schlake T et al., RNA Biology, Oct. 2012. More...

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect
Fotin-Mleczek M et al., Journal of Gene Medicine, June 2012. More...

Protein expression from exogenous mRNA: Uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway
Lorenz C et al., RNA Biology, July 2011. More...

Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity
Fotin-Mleczek M et al., Journal of Immunotherapy, Jan. 2011. More...

mRNA: delivering an antitumor message?
Van Lint S et al., Immunotherapy, May 2011. More...

Intradermal Vaccinations With RNA Coding for TAA Generate CD8(+) and CD4(+) Immune Responses and Induce Clinical Benefit in Vaccinated Patients
Rittig SM et al., Molecular Therapy, Dec. 2010. More...

Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients
Weide B et al., Journal of Immunotherapy, June 2009. More...

Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent
Probst J et al., Gene Therapy, Aug. 2007. More...

Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA
Scheel B et al., European Journal of Immunology, Oct. 2006. More...

Characterization of the ribonuclease activity on the skin surface
Probst J et al., Genetic Vaccines and Therapy, May 2006. More...

Vaccination with messenger RNA
Pascolo S, Methods in Molecular Medicine, Review 2006. More...

Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas
Carralot JP et al., Genetic Vaccines and Therapy, Aug. 2005. More...

Human peripheral blood mononuclear cells transfected with messenger RNA stimulate antigen-specific cytotoxic T-lymphocytes in vitro
Teufel R et al., Cellular and Molecular Life Sciences, Aug. 2005. More...

Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA
Scheel B et al., European Journal of Immunology, May 2005. More...

Co-transfection of messenger RNA and siRNA as a method to study the efficiency of siRNA
Mutzke T et al., Nucleosides Nucleotides and Nucleic Acids, 2005. More...

RNA-based Therapies
Pascolo S, Drug Discovery Handbook, by Shayne Cox Gad, July 2005. More...

Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines
Carralot JP et al., Cellular and Molecular Life Sciences, Sept. 2004. More...

Messenger RNA-based vaccines
Pascolo S, Expert Opinion on Biological Therapy, Aug. 2004. More...

Immunostimulating capacities of stabilized RNA molecules
Scheel B et al., European Journal of Immunology, Feb. 2004. More...

In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies
Hoerr I et al., European Journal of Immunology, Jan. 2000. More...